Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 151-160 , June 2003

Early diagnosis and surgical management of prostate cancer

  • Kate D Linton
    • ,
  • Freddie C Hamdy

      Affiliations

    • Corresponding Author InformationCorrespondence to: F.C. Hamdy MD, FRCSEd (Urol), Professor and Head of Urology, Academic Urology Unit, Royal Hallamshire Hospital, Glossop Road, Sheffield S10 2JF, UK. Tel.: +44-0-114-271-2154; Fax: +44-0-114-271-2268

References 

  1. Ahmedin J, Thomas A, Murray T, Thun M. CA Cancer J. Clin. 2002;52(1):23–47
  2. Jenson OM, Esteve J, Renard H. Cancer in the European Community and its member states. Eur. J. Cancer. 1990;26:1167–1256
  3. Wilson JMG, Jungner G. Principles and practice of screening for disease. Geneva, World Health Organization, 1968. (Public health papers No. 34)
  4. Bartsch G, Horninger W, Klocker H, Reissigl A, Oberaigner W, Schonitzer D, et al. Tyrol Prostate Cancer Screening Group: Prostate cancer mortality after introduction of prostate-specific antigen mass screening in the Federal State of Tyrol, Austria. Urology. 2001;58:417–424
  5. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJJ, et al. Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 1991;324:1156–1161
  6. Brawer MK, Cheli CD, Neaman IE, Goldblatt J, Smith C, Schawrtz MK, et al.  Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. J. Urol. 2000;163:1476–1480
  7. Recker F, Kwiatkowski MK, Piironen T, Petterson K, Huber A, Lummen G, et al.  Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ confined cancer compared with prostatic specific antigen. Urology. 2000;55:481–485
  8. Barry MJ. Clinical practice. Prostate-specific-antigen testing for early diagnosis of prostate cancer. N. Engl. J. Med. 2001;344:1373–1377
  9. Lilja H. Role of hK2, free PSA, and complexed PSA measurements in the very early detection of prostate cancer. Eur. Urol. 2001;39(Suppl 4):47–48
  10. Haggman MJ, Macoska JA, Wojno KJ, Oesterling JE. The relationship between prostatic intraepithelial neoplasia and prostate cancer: critical issues. J. Urol. 1997;158:12–22
  11. Wilkinson BA, Hamdy FC. State-of-the-art staging in prostate cancer. BJU Int. 2001;87(5):423–430
  12. Schroder FH, van der Maas P, Beemsterboer P, Kruger AB, Hoedemaeker R, Rietbergen J, et al. Evaluation of the digital rectal examination as a screening test for prostate cancer. Rotterdam section of the European Randomized Study of Screening for Prostate Cancer. J. Natl. Cancer Inst. 1998;90:1817–1823
  13. Holmberg L, Bill-Axelson A, Helgesen F, Salo JO, Folmerz P, Haggman M, et al. A randomized trial comparing radical prostatectomy with watchful waiting in early prostate cancer; Scandinavian Prostatic Cancer Group Study Number 4. N. Engl. J. Med. 2002;347:781–789
  14. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, et al. Quality of life after radical prostatectomy or watchful waiting. Scandinavian Prostatic Cancer Group Study Number 4. N. Engl. J. Med. 2002;347:790–796
  15. Begg CB, Riedel ER, Bach PB, Kattan MW, Schrag D, Warren JL, et al. Variations in morbidity after radical prostatectomy. N. Engl. J. Med. 2002;346:1138–1144
  16. Donovan J, Mills N, Smith M, Brindle L, Jacoby A, Peters T, et al. Improving design and conduct of randomised trials by embedding them in qualitative research: ProtecT (prostate testing for cancer and treatment) study. BMJ. 2002;325:766–770
  17. Barnes RW. Survival with conservative therapy. JAMA. 1969;210(2):331
  18. Johansson JE, Adami HO, Andersson SO, Bergstrom R, Krusemo UB, Kraaz W. Natural history of prostate cancer: a population based study of 223 untreated patients. Lancet. 1989;1:799–803
  19. Johansson JE, Holmberg L, Johansson S, Bergstrom R, Adami HO. Fifteen-year survival in prostate cancer. A prospective, population-based study in Sweden. JAMA. 1997;277:467–471
  20. Chodak GW, Thisted RA, Gerber GS, Johansson JE, Adolfsson J, Jones GW, et al. Results of conservative management of clinically localized prostate cancer. N. Engl. J. Med. 1994;330:242–248
  21. Albertsen PC, Frybeck DG, Storer BE, Kolon TF, Fine J. Long-term survival among men with conservatively treated localized prostate cancer. JAMA. 1995;274:626–631
  22. Albertsen PC, Hanley JA, Gleason DF, Barry MJ. A competing risk analysis of men age 55–74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA. 1998;280:975–980
  23. Oliver SE, Gunnell D, Donovan JL. Comparison of trends in prostate-cancer mortality in England and Wales and the USA. Lancet. 2000;355:1788–1789
  24. Lu-Yao G, Albertsen PC, Stanford JL, Stukel TA, Walker-Corkery ES, Barry MJ. Natural experiment examining impact of aggressive screening and treatment on prostate cancer mortality in two fixed cohorts from Seattle area and Connecticut. BMJ. 2002;325:740
  25. Wilt TJ, Brawer MK. The prostate cancer intervention versus observation trial (PIVOT). Oncology (Huntingt). 1997;11(8):1133
  26. Partin AW, Yoo JK, Carter HB, Parson JD, Chan DW, Epstein JI, et al.  The use of prostatic specific antigen, clinical stage and Gleason score to predict pathological stage in men with prostate cancer. J. Urol. 1993;150:110–114
  27. Carvalhal GF, Smith DS, Mager DE, Ramos C, Catalona WJ. Digital rectal examination for detecting prostate cancer at prostatic specific antigen levels of 4ng/mL or less. J. Urol. 1999;161:835–839
  28. Nadji M, Tabei SZ, Castro A, Chu TM, Murphy GP, Wang MC, et al.  Prostatic-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer. 1981;1229–1232
  29. Catalona WJ, Smith DS, Ratliff L, et al.  Measurement of prostate specific antigen in serum as a screening test for prostate cancer. N. Engl. J. Med. 1991;324:1156–1161
  30. Christensson A, Bjork T, Nilsson O, et al.  Serum prostate specific antigen complexed to α1-antichymotrypsin as an indicator of prostate cancer. J. Urol. 1993;150:100
  31. Luderer AA, Chen Y, Thiel R, et al.  Measurement of the proportion of free to total PSA improves diagnostic performance of PSA in the diagnostic grey zone of total PSA. Urology. 1995;46:187–194
  32. Catalona WJ, Partin AW, Slawin KM, et al.  Use of percentage of free prostate-specific antigen to enhance differentiation of prostate cancer from benign prostatic disease: a prospective multicentre clinical trial. J. Am. Med. Assoc. 1998;279:1542–1547
  33. Catalona WJ, Southwick PC, Slawin KM, et al.  Comparison of percent free PSA, PSA density, and age-specific PSA cut-offs for prostate cancer detection and staging. Urology. 2000;56:255–260
  34. Benson MC, Whang IS, Olsson CA, et al.  The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum prostate specific antigen. J. Urol. 1992;147:817–821
  35. Benson MC, Whang IS, Pantuck A, et al.  Prostate specific antigen density: a means of distinguishing benign prostatic hypertrophy and prostate cancer. J. Urol. 1992;147:815–816
  36. Djavan B, Zlotta AR, Byttebier G, et al.  Prostate specific antigen density of the transition zone for early detection of prostate cancer. J. Urol. 1998;160:411–419
  37. Carter HB, Morrell CH, Pearson JD, et al.  Estimation of prostatic growth using serial prostate-specific antigen measurements in men with and without prostatic disease. Cancer Res. 1992;52:3323–3328
  38. Carter HB, Pearson JD, Metter J, et al.  Longitudinal evaluation of prostate specific antigen levels in men with and without prostate disease. JAMA. 1992;267:2215
  39. Pearson JD, Carter HB. Natural history of changes in prostate specific antigen in early stage prostate cancer. J. Urol. 1994;152:1743–1748
  40. Carter HB, Pearson JD, Chan DW, et al.  Prostate specific antigen variability in men without prostate cancer: effect of sampling interval on prostate-specific antigen velocity. Urology. 1995;45:591
  41. Oesterling JE, Jacobsen SJ, Chute CG, et al.  Serum prostate-specific antigen in the community-based population of healthy men: establishment of age-specific reference ranges. JAMA. 1993;270:860–864
  42. Dalkin BL, Ahmann FR, Kopp JB. Prostate specific antigen levels in men older than 50 years without clinical evidence of prostate carcinoma. J. Urol. 1993;150:1837–1839
  43. Christensson A, Laurell C-B, Lilja H. Enzymatic activity of prostate-specific antigen and its reactions with extracellular serine proteinase inhibitors. Eur. J. Biochem. 1990;194:755–763
  44. Catalona WJ, Smith DS, Wolfert R, Wang TJ, Rittenhouse H, Ratliff TL, et al. Evaluation of percentage of free serum prostate-specific antigen to improve specificity of prostate cancer screening. JAMA. 1995;274:1214–1220
  45. Arcangeli CG, Shepherd DL, Smith DS, et al.  Correlation of percent free PSA with pathologic features of prostatic carcinomas. J. Urol. 1996;155:415
  46. Pannek J, Rittenhouse HG, Chan DW, Epstein JI, Walsh PC, Partin AW, et al.  The use of percent free prostatic-specific antigen for staging of men with clinically localised prostate cancer. J. Urol. 1998;159:1238–1242
  47. Pannek J, Subong ENP, Jones KA, Marschke PL, Epstein JI, Chan DW, et al.  The role of free/total prostatic-specific antigen ratio in the prediction of final pathological stage for men with clinically localised prostate cancer. Urology. 1996;48:51–54
  48. Lerner SE, Jacobson SJ, Lilja H, Berg stralh EJ, Ransom J, Klee GG, et al.  Free complexed and total serum prostate specific antigen concentrations and their proportions in predicting stage, grade, and deoxyribonucleic acid ploidy in patients with adenocarcinoma of the prostate. Urology. 1996;48:224–240
  49. Catalona WJ, Smith DS, Ornstein DK. Prostate cancer detection in men with serum PSA concentrations of 2.6–4.0ng/ml and benign prostate examination: enhancement of specificity with free PSA measurements. JAMA. 1997;277:1452–1455
  50. Recker F, Kwiatkowski MK, Piironen T, Petterson K, Huber A, Lummen G, et al.  Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ confined cancer compared with prostatic specific antigen. Urology. 2000;55:481–485
  51. Haese A, Becker C, Noldus J, Graefen M, Huland E, Huland H, et al.  Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. J. Urol. 2000;163(May):1491–1497
  52. Watanabe H, Kato H, Kato T, Masayoshi M. Diagnostic application of the ultrasonotomography for the prostate. Jpn. J. Urol. 1968;59:273–279
  53. Lorentzen T, Nerstom H, Iverson P, Torp-Pederson ST. Local staging of prostate cancer with transrectal ultrasound: a literature review. Prostate Supp. 1992;4:11–16
  54. Rifkin MD, Zerhouni EA, Gatsonis CA, Quint LE, Paushter DM, Epstein JI, et al.  Comparison or magnetic resonance imaging and ultrasonography in staging early prostate cancer-results of a multi-institutional cooperative trial. N. Engl. J. Med. 1990;323:621–626
  55. Smith JA, Scardino PT, Resnick MI, Hernandez AD, Rose SC, Egger MJ, et al.  Transrectal ultrasound versus digital rectal examination for the staging of carcinoma of the prostate: results of a prospective multi-institutional trial. J. Urol. 1997;157:902–906
  56. Hardeman SW, Causey JQ, Hickey DP, Soloway MS. Transrectal ultrasound for staging prior to radical prostatectomy. Urology. 1989;34:175–180
  57. Liebross RH, Pollack A, Lankford SP, Zagars GK, von Eshenbach AC, Geara FB. Transrectal ultrasound for staging prostate carcinoma prior to radiation therapy. Cancer. 1999;85:1577–1585
  58. Ukimura O, Troncoso P, Ramirez EI, Babaian RJ. Prostate cancer staging: correlation between ultrasound determined tumor contact length and pathologically confirmed extraprostatic extension. J. Urol. 1998;159:1251–1259
  59. Balaji KC, Fair WR, Feleppa EJ, et al.  The role of advanced 2 and 3-dimensional ultrasound for detecting prostate cancer. J. Urol. 2002;168:2422–2425
  60. Rodriguez LV, Terris MK. Risks and complications of transrectal ultrasound guided prostate needle biopsy: a prospective study and review of the literature. J. Urol. 1998;160:2115–2120
  61. Young HH. The early diagnosis and radical cure of carcinoma of the prostate. Being a study of 40 cases and presentation of a radical operation, which was carried out in four cases. John Hopkins Hosp Bull. 1905;16:315–321
  62. Millin T. Retropubic Urinary Surgery. Baltimore, MD: Williams and Wilkins; 1947;
  63. Walsh PC, Donker PJ. Impotence following radical prostatectomy: insight into etiology and prevention. J. Urol. 1982;128:492–497
  64. Walsh PC, Lepor H, Eggleston JC. Radical prostatectomy with preservation of sexual function: anatomical and pathological considerations. Prostate. 1983;4:473–485
  65. Myers RP. Prostate shape, external striated urethral sphincter, and radical prostatectomy: the apical dissection. J. Urol. 1987;138:543–550
  66. Catalona WJ, Ramos CG, Carvalhal GF. Contemporary results of anatomic radical prostatectomy. CA Cancer J. Clin. 1999;49:282–296
  67. Burkhard FC, Bader P, Schneider E, Markwalder R, Studer UE. Reliability of preoperative values to determine the need for lymphadenectomy in patients with prostate cancer and meticulous lymph node dissection. Eur. Urol. 2002;42(2):84–90 discussion 90-2
  68. Schuessler W, Kavoussi LR, Clayman R, et al.  Laparoscopic radical prostatectomy: initial case report. J. Urol. 1992;4:246A
  69. Guillonneau B, Valancien G. Laparoscopic radical prostatectomy: the Montsouris experience. J. Urol. 2000;163:418–422

PII: S0305-7372(03)00096-3

doi: 10.1016/S0305-7372(03)00096-3

Cancer Treatment Reviews
Volume 29, Issue 3 , Pages 151-160 , June 2003

Article Tools